Physician profile
Mauricio Y Bitran
NPI 1700990108
$6,234.87
in general payments reported to CMS, 2019-2025
30 companies · $553 in 2025
The $553 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,862 · 2020: $212 · 2021: $606 · 2022: $338 · 2023: $419 · 2024: $245 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.89 |
| Education | $234.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $3,500.00 | 2019 | |
| Astellas Pharma US INC | $434.55 | 2023-2025 | Veozah |
| Abbvie INC. | $418.38 | 2019-2023 | Lo Loestrin Fe |
| Coopersurgical, INC. | $378.44 | 2019-2025 | Paragard T 380a, Wallach Cryosurgical Equipment, Paragard T 380a |
| Therapeuticsmd, INC. | $274.65 | 2019-2022 | |
| Hologic Sales and Service, LLC | $158.29 | 2019-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Daiichi Sankyo INC. | $122.17 | 2019-2021 | |
| Evofem Biosciences, INC. | $119.09 | 2021-2025 | Phexxi, Solosec, Phexx |
| Biogen, INC. | $106.94 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $81.45 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $77.86 | 2019-2021 | |
| Axonics, INC. | $57.94 | 2023 | Axonics |
| Organon LLC | $57.80 | 2022-2023 | Nexplanon |
| Exeltis, USA INC. | $52.25 | 2023 | Slynd |
| Millicent US INC | $45.00 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alydia Health | $38.43 | 2021 | |
| Pfizer INC. | $32.70 | 2022 | |
| Allergan, INC. | $32.38 | 2019 | |
| Baxter Healthcare | $30.22 | 2025 | Perclot |
| Lupin INC. | $29.43 | 2020 | |
| Boston Scientific Corporation | $27.82 | 2022 | |
| Duchesnay USA Incorporated | $25.53 | 2019 | |
| Optumhealth Care Solutions, LLC | $21.30 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Agile Therapeutics, INC. | $19.74 | 2021 | |
| Mayne Pharma Commercial LLC | $18.23 | 2021 | |
| Organogenesis INC. | $17.27 | 2023 | Puraply |
| Merck Sharp & Dohme LLC | $14.93 | 2020 | |
| Mission Pharmacal Company | $14.64 | 2021 | |
| Sumitomo Pharma America, INC. | $13.82 | 2025 | Gemtesa |
| Mallinckrodt Enterprises LLC | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Bitran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.